Refractive Management/Intervention Panel - 2022 Financial Disclosures
Deborah S. Jacobs, MD, Chair
Cloudbreak Pharma, Dompe, TECLens - C
UpToDate - P
TECLens - PS
Natalie A. Afshari, MD
Aescula Tech, Alpine Biotherapeutics, Claire Biotherapeutics, Trefoil - C, O
Claris Biotherapeutics, Dompe Pharmaceuticals, Galaxo Smith Kline - C
National Eye Institute, National Institutes of Health, Research to Prevent Blindness - S
Rachel J. Bishop, MD
No financial relationships to disclose
Jeremy D. Keenan, MD, MPH
No financial relationships to disclose
Jimmy K. Lee, MD
No financial relationships to disclose
Tueng T. Shen, MD, PhD
No financial relationships to disclose
Susan Vitale, PhD, MHS, Methodologist
No financial relationships to disclose
KEY:
C = Consultant/Advisor (consultant fee, paid advisory boards or fees for attending a meeting [for the past 1 year])
E = Employee (employed by a commercial entity)
L = Lecture Fees (lecture fees [honoraria], travel fees or reimbursement when speaking at the invitation of a commercial entity)
O = Equity Owner (ownership/stock options of publicly or privately owned firms [excluding mutual funds] with manufacturers of commercial ophthalmic products or commercial ophthalmic services)
P = Patents/Royalty (patents and/or royalties that might be viewed as creating a potential conflict of interest)
S = Grant Support (grant support for the past 1 year [all sources] and all sources used for this project if this form is an update for a specific talk or manuscript with no time limitation)